QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 intensity-therapeutics-stock-cools-after-hours-following-395-surge-what-you-should-know

Intensity Therapeutics shares plunged 31.9% after-hours following the publication of Phase 1/2 trial results for its cancer the...

 intensity-therapeutics-reports-early-radiological-and-pathological-results-with-int230-6-demonstrating-high-drug-absorption-tumor-necrosis-and-evidence-of-immune-activation

A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patie...

 benchmark-maintains-speculative-buy-on-intensity-therapeutics-lowers-price-target-to-15

Benchmark analyst Robert Wasserman maintains Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and lowers the pric...

 brookline-capital-upgrades-intensity-therapeutics-to-buy-announces-3-price-target

Brookline Capital analyst Kumaraguru Raja upgrades Intensity Therapeutics (NASDAQ:INTS) from Hold to Buy and announces $3 pr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION